Biomea Fusion Inc

NASDAQ BMEA

Download Data

Biomea Fusion Inc Cash Return on Investment (CROI) 3 year CAGR for the year ending December 31, 2022

Biomea Fusion Inc Cash Return on Investment (CROI) 3 year CAGR is NA for the year ending December 31, 2022. The cash return on investment ratio measures the profitability of a company's total investments based on its operating cash flow. It is calculated by dividing operating cash flow by total investments. This ratio indicates how effectively the company generates cash flow from its investments. A higher ratio suggests more efficient cash flow generation from the investments made. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Biomea Fusion Inc Cash Return on Investment (CROI) for the year ending December 31, 2022 was -54.28, a -4,442.01% change year over year.
  • Biomea Fusion Inc Cash Return on Investment (CROI) for the year ending December 31, 2021 was -1.19.
NASDAQ: BMEA

Biomea Fusion Inc

CEO Mr. Thomas Andrew Butler
IPO Date April 16, 2021
Location United States
Headquarters 900 Middlefield Road, Redwood City, CA, United States, 94063
Employees 110
Sector Healthcare
Industry Biotechnology
Description

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Similar companies

EWTX

Edgewise Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

DSGN

Design Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email